Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImageneBio, Inc. stock logo
IMA
ImageneBio
$9.14
-0.7%
$14.32
$7.95
$23.28
$36.98M0.4939,893 shs55,104 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$11.13
-5.0%
$12.98
$9.77
$27.38
$148.74M0.39145,177 shs334,521 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.96
+2.6%
$1.70
$0.63
$2.75
$162.34M0.61.08 million shs1.98 million shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$1.97
-4.8%
$2.08
$1.31
$5.94
$147.02M0.76499,491 shs802,769 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%+14.82%-38.20%-43.58%-55.46%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-8.09%-18.64%-10.46%+18.28%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%+8.89%+16.67%+18.79%+35.17%
Nkarta, Inc. stock logo
NKTX
Nkarta
0.00%-12.83%-10.45%+5.91%-69.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImageneBio, Inc. stock logo
IMA
ImageneBio
$9.14
-0.7%
$14.32
$7.95
$23.28
$36.98M0.4939,893 shs55,104 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$11.13
-5.0%
$12.98
$9.77
$27.38
$148.74M0.39145,177 shs334,521 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.96
+2.6%
$1.70
$0.63
$2.75
$162.34M0.61.08 million shs1.98 million shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$1.97
-4.8%
$2.08
$1.31
$5.94
$147.02M0.76499,491 shs802,769 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%+14.82%-38.20%-43.58%-55.46%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-8.09%-18.64%-10.46%+18.28%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%+8.89%+16.67%+18.79%+35.17%
Nkarta, Inc. stock logo
NKTX
Nkarta
0.00%-12.83%-10.45%+5.91%-69.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.50
Moderate Buy$35.50288.40% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50174.03% Upside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$4.50129.59% Upside
Nkarta, Inc. stock logo
NKTX
Nkarta
3.00
Buy$13.60590.36% Upside

Current Analyst Ratings Breakdown

Latest IMA, LFVN, NKTX, and MIST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$4.00
8/14/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$14.00 ➝ $12.00
8/13/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
7/25/2025
ImageneBio, Inc. stock logo
IMA
ImageneBio
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$25.00 ➝ $23.00
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImageneBio, Inc. stock logo
IMA
ImageneBio
$9.16M4.01N/AN/A$31.33 per share0.29
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.62$1.04 per share10.66$2.75 per share4.05
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/A$0.25 per shareN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$5.78 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.7415.04N/A4.29%33.75%15.26%11/4/2025 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%11/11/2025 (Estimated)
Nkarta, Inc. stock logo
NKTX
Nkarta
-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)

Latest IMA, LFVN, NKTX, and MIST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17$0.17N/A$0.15$57.93 million$55.11 million
8/12/2025Q2 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.18-$0.20-$0.02-$0.20N/AN/A
8/12/2025Q2 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.37-$0.31+$0.06-$0.31N/AN/A
7/24/2025Q2 2025
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$0.14-$0.06+$0.08-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.62%N/A24.32%3 Years
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A

Latest IMA, LFVN, NKTX, and MIST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/26/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.57%9/8/20259/8/20259/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/A
13.52
13.52
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.87
1.11
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.97
4.97
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
15.67
15.67

Institutional Ownership

CompanyInstitutional Ownership
ImageneBio, Inc. stock logo
IMA
ImageneBio
75.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%

Insider Ownership

CompanyInsider Ownership
ImageneBio, Inc. stock logo
IMA
ImageneBio
5.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
19.50%
Nkarta, Inc. stock logo
NKTX
Nkarta
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImageneBio, Inc. stock logo
IMA
ImageneBio
704.02 million3.78 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.69 million10.07 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3084.99 million68.42 millionOptionable
Nkarta, Inc. stock logo
NKTX
Nkarta
14071.03 million65.06 millionOptionable

Recent News About These Companies

Nuveen LLC Invests $258,000 in Nkarta, Inc. $NKTX
Nkarta to Participate in a September Investor Conference
Nkarta, Inc. Reports Q2 2025 Financial Results
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?
Nkarta, Inc. (NKTX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ImageneBio stock logo

ImageneBio NASDAQ:IMA

$9.14 -0.06 (-0.65%)
As of 09/12/2025 04:00 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$11.13 -0.59 (-5.03%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$11.28 +0.15 (+1.30%)
As of 09/12/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.96 +0.05 (+2.62%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.96 0.00 (-0.26%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$1.97 -0.10 (-4.83%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.03 (+1.57%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.